Lupus Trial, Recruiting NCT06458075 Sponsor: Duke University Condition: Lupus
Back to Lupus

Lupus Trial, Recruiting

NCT06458075
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For patients:

  • You are 18 years of age or older
  • You speak English and are able to give your own consent to participate
  • You have been diagnosed with lupus (SLE) and are being treated by a doctor who is taking part in this study
  • You have been prescribed at least one lupus medication, and you fill your prescriptions at a pharmacy that is connected to a specific electronic records system used in this study (confirm with trial site)

For healthcare providers (this trial also involves doctors and clinical staff):

  • You are a rheumatology doctor, advanced practice provider, or fellow at one of the two participating academic hospitals
  • You provide outpatient rheumatology care for at least half a day per week

Who may not be able to join:

For patients:

  • You do not speak English
  • Your only lupus medication is a steroid (such as prednisone)
  • You are accompanied by someone who is not willing to wait outside during your visit, does not want the visit to be audio recorded, is a minor without a parent or legal guardian present, or is unable to give their own consent (confirm with trial site)

For healthcare providers:

  • You work at Duke University and were already involved in an earlier version of this study
  • You are planning to leave your current institution within 12 months of joining the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kai Sun, MD, Duke University

Phone: 919- 681- 7417

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
1 July 2024
Est. completion
1 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Frequency of adherence discussions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov